The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is set to run from June 3 to…
The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical stocks short interest decreased.
A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation to a patent expiry and the opening of the floodgates…
AbbVie reported its first-quarter financial results and guidance before the markets opened on Thursday.
Chris Lange The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical companies generate an estimated $300…
These four Jefferies Franchise Picks are rated Buy and pay the highest dividends. They make good sense for investors now.
The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Now all investor eyes turn to first-quarter earnings results. With interest rates still very low, investors looking to add capital should still focus on top dividend-paying stocks.
Long-term growth investors looking for a degree of safety and value should consider some of these outstanding companies. While the sentiment may be less than stellar now, massive drug pricing changes anytime…
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.
The February 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest decreased.
In a recent research report, Jefferiesfocused on some large cap stocks that are still trading way below their 52-week highs.
The top analyst upgrades, downgrades and initiations seen from Monday, March 7, include Enbridge, Micron Technology, Sun Life Financial, Starbucks, Stratasys and Wynn Resorts.
The top analyst upgrades, downgrades and initiations seen from Friday, February 26, include American Water Works, Autodesk, Kraft Heinz, Palo Alto Networks, Toyota and Vipshop.
